The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...

That hasn’t stopped Bexsero’s steady growth, with sales approaching the $1 billion threshold last year, while Menveo added another ... suggested that the 5-in-1 vaccine could eventually ...

Non-inferiority of Menveo to Menactra in adolescents ... administration did not increase reactogenicity 5. Analysing issues for meningococcal vaccines is Lee H. Harrison, M.D., Professor of ...

Penmenvy combines the antigenic components of GSK's Bexsero and Menveo vaccines into a single vaccine ... and the company has provided guidance for a 3%-5% increase in sales and a 6%-8% rise in core ...

Menveo, a meningococcal vaccine, plays a critical role in controlling the spread of meningitis by offering protection against multiple strains of Neisseria meningitidis, a leading cause of ...